Advanced search
Publication Cover
OncoImmunology Volume 10, 2021 - Issue 1
Submit an article Journal homepage
1,922
Views
10
CrossRef citations to date
0
Altmetric
Author’s View

Crizotinib and ceritinib trigger immunogenic cell death via on-target effects

Adriana Petrazzuoloa Team “Metabolism, Cancer & Immunity”,Centre De Recherche Des Cordeliers, Inserm UMRS1138, Université De Paris, Sorbonne Université, Paris, France;b Cell Biology and Metabolomics Platforms, Gustave Roussy Cancer Campus, Villejuif, FranceView further author information
,
Maria Perez-Lanzona Team “Metabolism, Cancer & Immunity”,Centre De Recherche Des Cordeliers, Inserm UMRS1138, Université De Paris, Sorbonne Université, Paris, France;b Cell Biology and Metabolomics Platforms, Gustave Roussy Cancer Campus, Villejuif, FranceORCID Iconhttps://orcid.org/0000-0002-6306-6520View further author information
ORCID Icon,
Peng Liua Team “Metabolism, Cancer & Immunity”,Centre De Recherche Des Cordeliers, Inserm UMRS1138, Université De Paris, Sorbonne Université, Paris, France;b Cell Biology and Metabolomics Platforms, Gustave Roussy Cancer Campus, Villejuif, FranceORCID Iconhttps://orcid.org/0000-0002-1682-9222View further author information
ORCID Icon,
M. Chiara Maiuria Team “Metabolism, Cancer & Immunity”,Centre De Recherche Des Cordeliers, Inserm UMRS1138, Université De Paris, Sorbonne Université, Paris, France;b Cell Biology and Metabolomics Platforms, Gustave Roussy Cancer Campus, Villejuif, FranceView further author information
&
Guido Kroemera Team “Metabolism, Cancer & Immunity”,Centre De Recherche Des Cordeliers, Inserm UMRS1138, Université De Paris, Sorbonne Université, Paris, France;b Cell Biology and Metabolomics Platforms, Gustave Roussy Cancer Campus, Villejuif, France;c Pôle De Biologie, Hôpital Européen Georges Pompidou, ; Paris, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9334-4405View further author information
ORCID Icon
Article: 1973197 | Received 02 Aug 2021, Accepted 23 Aug 2021, Published online: 25 Oct 2021

Figures & data

Figure 1. On-target effects of ALK inhibitors inducing ICD. The scheme recapitulates the major arguments suggesting that crizotinib and ceritinib indeed stimulate ICD via on-target effects, namely (a) low-dose effects that are expected to inhibit ALK but not any other tyrosine kinase; (b) mimicry by genetic inhibition of ALK, (c) mimicry by pharmacological inhibition of down-stream targets and (d) abolition of ICD-inducing effects after selection for resistance

Figure 1. On-target effects of ALK inhibitors inducing ICD. The scheme recapitulates the major arguments suggesting that crizotinib and ceritinib indeed stimulate ICD via on-target effects, namely (a) low-dose effects that are expected to inhibit ALK but not any other tyrosine kinase; (b) mimicry by genetic inhibition of ALK, (c) mimicry by pharmacological inhibition of down-stream targets and (d) abolition of ICD-inducing effects after selection for resistance

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.